All semaglutide articles
-
Opinion
Compounding problems
Regulating the line between a vital service and grey-market profiteering is a mess
-
Business
Weight-loss drug shortages prompt copycats and counterfeits
Novo Nordisk and Eli Lilly have struggled to meet huge demand for new hormone mimic obesity treatments